Rheopheresis is an extracorporal selective double-filtration procedure with an initial separation of plasma from the whole blood and a further filtration of the plasma through a second filter in order to eliminate a certain number of high molecular weight proteins such LDL, Lp(a), fibrinogen, α2-macroglobulin, Factor von Willebrand, and IgM Immunoglobulin.
Methods:
In this narrative review we discuss the available data on the effects of Rheopheresis in various clinical conditions.
Results:
Rheopheresis is considerd to exert a rapid effect on clinical conditions associated with seriously affected microcirculation and rheologic parameters such as, the dry age-related macular degeneration (AMD), sudden sensorineural hearing loss (SSHS), peripheral artery disease (PAD), calciphylaxis, systemic sclerosis and diabetic foot.
Conclusions:
Rheopheresis is a promising technique for conditions associated with affected microcirculatory rheologic parameters
RamunniABresciaPDe FinoG, et al. Therapeutic apheresis in peripheral and retinal circulatory disorders. Clin Res Cardiol Suppl2012; 7: 41–44.
2.
PadmanabhanAConnelly-SmithLAquiN, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Writing Committee of the American Society for Apheresis: the Eighth Special Issue. J Clin Apher2019; 34(3): 171–354.
3.
KorstenPMüllerGARademacherJG, et al. Rheopheresis for digital ulcers and Raynaud’s phenomenon in systemic sclerosis refractory to conventional treatments. Front Med2019; 6: 208.
4.
KirschkampTSchmid-SchönbeinHWeinbergerA, et al. Effects of fibrinogen and α2-Macroglobulin and their apheretic elimination on general blood rheology and rheological characteristics of red blood cell aggregates. Ther Apher Dial2008; 12(5): 360–367.
5.
KlingelRFassbenderCFassbenderT, et al. Rheopheresis: rheologic, functional, and structural aspects. Ther Apher2000; 4(5): 348–357.
6.
Schuff-WernerPHoldtB. Selective hemapheresis, an effective new approach in the therapeutic management of disorders associated with rheological impairment: mode of action and possible clinical indications. Artif Organs2002; 26(2): 117–123.
7.
BlahaMAndrysCLangrovaH, et al. Changes of the complement system and rheological indicators after therapy with rheohemapheresis. Atheroscler Suppl2015; 18(5): 140–145.
8.
MelindaVÁgnesDNorbertN, et al. Rheopheresis in vascular diseases. Clin Hemorheol Microcirc2016; 64(4): 977–987.
9.
WorelNMansouri TaleghaniBStrasserE. Recommendations for therapeutic apheresis by the section “Preparative and Therapeutic Hemapheresis” of the German Society for Transfusion Medicine and Immunohematology. Transfus Med Hemother2019; 46: 394–406.
10.
KossMJKurzPTsobanelisT, et al. Prospective, randomized, controlled clinical study evaluating the efficacy of rheopheresis for dry age-related macular degeneration. Dry AMD treatment with rheopheresis Trial-ART. Graefes Arch Clin Exp Ophthalmol2009; 247(10): 1297–1306.
11.
García-LayanaAThumannGGrollJ. Age macular degeneration: Etiology, prevention, individualized therapies, cell therapy, and tissue engineering. J Ophthalmol2014; 2014: 1–2.
12.
RencováEBláhaMStudničkaJ, et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft Drusen to the neovascular form. Acta Ophthalmol2011; 89(5): 463–471.
13.
BlahaMRencovaELangrovaH, et al. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. Atheroscler Suppl2013; 14(1): 179–184.
14.
PulidoJS; Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc2002; 100: 85–106; discussion 106-7.
15.
PulidoJSandersDWintersJL, et al. Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD). J Clin Apher2005; 20(3): 185–194.
16.
PulidoJSWintersJLBoyerD. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Ophthalmol Soc2006; 104: 221–231.
17.
KostalMDrsataJBláhaM, et al. Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss. J Otolaryngol Head Neck Surg2017; 46(1): 50.
18.
UllrichHKleinjungTSteffensT, et al. Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. J Clin Apher2004; 19(2): 71–78.
19.
ValbonesiMMoraFMoraR, et al. Rheopheresis for sudden hearing loss (SHL). Int J Artif Organs2004; 27(9): 806–809.
20.
BalletshoferBMStockJRittigK, et al. Acute effect of rheopheresis on peripheral endothelial dysfunction in patients suffering from sudden hearing loss. Ther Apher Dial2005; 9(5): 385–390.
21.
MösgesRKöberleinJHeibgesA, et al. Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial. Eur Arch Otorhinolaryngol2009; 266(7): 943–953.
22.
MosgesRKoberleinJErdtrachtB, et al. Quality of life in patients with idiopathic sudden hearing loss: comparison of different therapies using the medical outcome Short Form (36) Health Survey questionnaire. Otol Neurol2008; 29: 769–775.
23.
RamunniABresciaPQuarantaD, et al. Fibrinogen apheresis in the treatment of peripheral arterial disease. Blood Purif2007; 25(5–6): 404–410.
24.
KlingelRMummeCFassbenderT, et al. Rheopheresis in patients with ischemic diabetic foot syndrome: results of an open label prospective pilot trial. Ther Apher Dial2003; 7: 444–455.
25.
KlingelRErdtrachtBGaussV, et al. Rheopheresis in patients with critical limb ischemia--results of an open label prospective pilot trial. Ther Apher Dial2005; 9(6): 473–481.
26.
RamunniAPetraruloFGrassoC, et al. Acute and chronic effects of therapeutic apheresis. Atheroscler Suppl2013; 14(1): 83–87.
27.
KeitaAIBahABBaldeMC, et al. Success of rheopheresis to treat digital hypoperfusion ischemic syndrome. Ther Apher Dial2021; 25: 362–364.
28.
RobertTLionetABatailleS, et al. Rheopheresis: a new therapeutic approach in severe calciphylaxis. Nephrology2020; 25(4): 298–304.
29.
Naciri BennaniHJouveTBoudjemaaS, et al. Hemodialysis coupled with rheopheresis in calciphylaxis: a winning combination. J Clin Apher2019; 34(5): 631–633.
30.
BouderliqueEProvotFLionetA. Rheopheresis for adjuvant treatment in resistant calciphylaxis. Ther Apher Dial2018; 22(4): 413–414.
31.
HamichSRakotosonJMazereeuwM, et al. [Iatrogenic non uremic calciphylaxis: a case report]. Nephrol Ther2020; 16(7): 431–436.
32.
BerrouschotJBarthelHKösterJ, et al. Extracorporeal rheopheresis in the treatment of acute ischemic stroke: A randomized pilot study. Stroke1999; 30(4): 787–792.
33.
González-VicentMHerreroBGuillénM, et al. Using rheopheresis for stem cell transplantation-associated thrombotic microangiopathy (TA-TMA). Transfus Apher Sci2013; 49(2): 234–237.
34.
Maurizi-BalzanJJouveTNaciri-BennaniH, et al. [How to implement a complete apheresis program within a hemodialysis unit]. Nephrol Ther2019; 15(6): 439–447.
35.
KlingelRFassbenderCHeibgesA, et al. Rheonet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther Apher Dial2010; 14(3): 276–286.
36.
FingerRPKrohneTUCharbel IssaP, et al. Plasmapheresis for dry age-related macular degeneration—evidence based?Retina2009; 29(5): 569–572.
37.
KlingelRHeibgesAUygun-KiehneS, et al. Rheopheresis for sudden sensorineural hearing loss. Atheroscler Suppl2009; 10: 102–106.
LutzeSDaeschleinGKonschakeW, et al. Rheopheresis as a causal therapy option for systemic scleroderma (SSc). Clin Hemorheol Microcirc2017; 67(3–4): 229–240.
